In this tumor model, mice treated with CD19.CAR(I)IL12 NKTs showed improved tumor control (Fig. 4f and Fig. S6D) that led to increased overall survival (Fig. 4g) compared to mice treated with CD19.CAR-NKTs. Here, CD19 is linked to neoplasm.